← Back to Screener
Spruce Biosciences, Inc. Common Stock (SPRB)
Price$69.89
Favorite Metrics
Price vs S&P 500 (26W)-68.25%
Price vs S&P 500 (4W)10.88%
Market Capitalization$96.45M
All Metrics
Book Value / Share (Quarterly)$30.99
P/TBV (Annual)0.84x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-24.29
Price vs S&P 500 (YTD)-23.44%
Net Profit Margin (TTM)-1079.94%
EPS (TTM)$-53.34
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-53.34
EPS (Annual)$-50.83
ROI (Annual)-91.65%
Cash / Share (Quarterly)$35.64
ROA (Last FY)-73.49%
Revenue Growth TTM (YoY)-90.18%
EBITD / Share (TTM)$-51.16
ROE (5Y Avg)-88.74%
Operating Margin (TTM)-1143.37%
Cash Flow / Share (Annual)$-24.29
P/B Ratio2.27x
P/B Ratio (Quarterly)2.19x
Net Income / Employee (Annual)$-5
EV / Revenue (TTM)9.68x
Net Interest Coverage (TTM)-431.96x
ROA (TTM)-127.96%
EPS Incl Extra (Annual)$-50.83
Current Ratio (Annual)5.17x
Quick Ratio (Quarterly)5.13x
3-Month Avg Trading Volume0.04M
52-Week Price Return662.47%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.10
P/S Ratio (Annual)19.64x
Asset Turnover (Annual)0.11x
52-Week High$240.00
EPS Excl Extra (Annual)$-50.83
26-Week Price Return-59.50%
Quick Ratio (Annual)5.13x
13-Week Price Return-10.30%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.17x
Enterprise Value$47.549
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)37.04%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1079.94%
Cash / Share (Annual)$35.64
3-Month Return Std Dev97.91%
Net Income / Employee (TTM)$-5
ROE (Last FY)-91.65%
Net Interest Coverage (Annual)-431.96x
EPS Basic Excl Extra (Annual)$-50.83
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-53.34
ROI (TTM)-196.72%
P/S Ratio (TTM)19.64x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.90
Price vs S&P 500 (52W)627.38%
Year-to-Date Return-19.30%
5-Day Price Return8.98%
EPS Normalized (Annual)$-50.83
ROA (5Y Avg)-64.86%
Net Profit Margin (Annual)-1079.94%
Month-to-Date Return7.57%
Cash Flow / Share (TTM)$-1.43
EBITD / Share (Annual)$-50.68
Operating Margin (Annual)-1143.37%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-84.89%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-53.34
P/TBV (Quarterly)0.68x
P/B Ratio (Annual)2.19x
Pretax Margin (TTM)-1079.94%
Book Value / Share (Annual)$30.99
Price vs S&P 500 (13W)-13.16%
Beta3.66x
Revenue / Share (TTM)$0.00
ROE (TTM)-203.99%
52-Week Low$4.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.10
4.30
4.30
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SPRBSpruce Biosciences, Inc. Common Stock | 19.64x | -90.18% | — | — | $69.89 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Spruce Biosciences is a late-stage biopharmaceutical company developing therapies for rare endocrine disorders with significant unmet medical needs. Its pipeline includes Tralesinidase Alfa (TA-ERT) and Tildacerfont/Cortibon, a companion diagnostic co-developed with HMNC Brain Health. The company targets underserved patient populations through specialized therapeutic solutions.